Nandita Mohan

1 week ago | medicaldialogues.in | Nandita Mohan

In a first move Ajanta pharma one of the leaders in the cardiology segment, has announced the launch of Met XL AMT 25 mg. It is a triple-drug combination for managing hypertension with coronary artery disease (CAD) uncontrolled on dual therapy. Met XL AMT is the world’s first revolutionary FDC now available with flexible titration option without compromising efficacy, a triple fixed-dose combination of Metoprolol succinate (ER) 25 mg, Telmisartan 40 mg, and Amlodipine 5 mg.

2 weeks ago | medicaldialogues.in | Nandita Mohan

In a bid to make osteoporosis treatment affordable to Indian masses, Alkem Laboratories has slashed the price of its Teriparatide brand, Gemfrac. Until now Teriparatide has been available in India at a monthly cost of therapy ranging from ₹7,000/- to ₹10,000/- limiting accessibility for many patients. Alkem has revised the rate of its Teriparatide brand. Gemfrac to make it available at ₹4,000/- per month, making osteoporosis treatment more affordable and accessible.

1 month ago | medicaldialogues.in | Nandita Mohan

A recent review article published in the Journal of Cutaneous and Aesthetic Surgery, published by Scientific Scholar. Initially, the application of the follicular unit excision (FUE) technique for hair transplantation faced a challenge due to a significant occurrence of hair follicle damage. However, advancements in techniques, punch designs, and tools have successfully addressed this issue.

1 month ago | medicaldialogues.in | Nandita Mohan

This research article is published in the Case Reports in Clinical Radiology, published by Scientific Scholar. Neuroendocrine tumours (NETs) affecting the extrahepatic bile ducts are extremely uncommon, with limited documented cases in the literature. Biliary NETs often present with obstructive jaundice. They are commonly misdiagnosed as cholangiocarcinoma due to their similar clinical presentation.

1 month ago | medicaldialogues.in | Nandita Mohan

Micro Labs has announced the launch of Sitanorm-E, a fixed-dose combination (FDC) of Sitagliptin and Empagliflozin for the management of uncontrolled type 2 diabetes mellitus (T2DM). Sitanorm-E is the fixed-dose combination of Sitagliptin and Empagliflozin which is approved by DCGI for the management of type 2 diabetes mellitus in patients inadequately controlled on metformin monotherapy. Sitanorm-E tablets are available in two strengths: Sitanorm-E 10 mg and Sitanorm-E 25 mg.